View Post

Trodelvy Improves QOL in Triple-Negative Breast Cancer

In In The News by Barbara Jacoby

By: Greg Laub From: At the European Society for Medical Oncology (ESMO) virtual meeting, new data from the phase III ASCENT study was presented showing that patients with treatment-resistant metastatic triple-negative breast cancer (TNBC) who received sacituzumab govitecan (Trodelvy) had significant and clinically meaningful improvements in health-related quality of life (QOL). In this exclusive MedPage Today video, co-investigator Kevin …

View Post

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: AWARE-1 trial demonstrates pelareorep primes an adaptive immune response Systemic delivery yields robust pelareorep replication selectively in tumor cells Pelareorep administration increases CelTIL – known to be associated with positive clinical outcomes Peripheral T cell clonality emerges as potential predictive and prognostic biomarker Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, …